{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:42:49Z","timestamp":1791409369901,"version":"4.3.3"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":1670,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201470"],"award-info":[{"award-number":["OPP1201470"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BBS\/E\/I\/ 00007031"],"award-info":[{"award-number":["BBS\/E\/I\/ 00007031"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>mAbs are a possible adjunct to vaccination and drugs in treatment of influenza virus infection. However, questions remain whether small animal models accurately predict efficacy in humans. We have established the pig, a large natural host animal for influenza, with many physiological similarities to humans, as a robust model for testing mAbs. We show that a strongly neutralizing mAb (2\u201312C) against the hemagglutinin head administered prophylactically at 15 mg\/kg reduced viral load and lung pathology after pandemic H1N1 influenza challenge. A lower dose of 1 mg\/kg of 2\u201312C or a DNA plasmid\u2013encoded version of 2\u201312C reduced pathology and viral load in the lungs but not viral shedding in nasal swabs. We propose that the pig influenza model will be useful for testing candidate mAbs and emerging delivery platforms prior to human trials.<\/jats:p>","DOI":"10.4049\/jimmunol.2000429","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T18:38:53Z","timestamp":1593196733000},"page":"648-660","source":"Crossref","is-referenced-by-count":39,"title":["Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms"],"prefix":"10.1093","volume":"205","author":[{"given":"Adam","family":"McNee","sequence":"first","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0671-2565","authenticated-orcid":false,"given":"Trevor R F","family":"Smith","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Holzer","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Clark","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bessell","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghiabe","family":"Guibinga","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Brown","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-1888","authenticated-orcid":false,"given":"Katherine","family":"Schultheis","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fisher","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ramos","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Nunez","sequence":"additional","affiliation":[{"name":"Animal and Plant Health Agency-Weybridge , New Haw, Addlestone KT15 3NB ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Bernard","sequence":"additional","affiliation":[{"name":"Animal and Plant Health Agency-Weybridge , New Haw, Addlestone KT15 3NB ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-405X","authenticated-orcid":false,"given":"Simon","family":"Graham","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-0358","authenticated-orcid":false,"given":"Veronica","family":"Martini","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphany","family":"Chrun","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Xiao","sequence":"additional","affiliation":[{"name":"Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892-3203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Kash","sequence":"additional","affiliation":[{"name":"Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892-3203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9694-7228","authenticated-orcid":false,"given":"Jeffery K","family":"Taubenberger","sequence":"additional","affiliation":[{"name":"Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892-3203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Elliott","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute , Philadelphia, PA 19103"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute , Philadelphia, PA 19103"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-2180","authenticated-orcid":false,"given":"Peter","family":"Beverley","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, St Mary\u2019s Campus, Imperial College London , London W2 1PG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Rijal","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine, University of Oxford , Oxford OX3 9DS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Weiner","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute , Philadelphia, PA 19103"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Townsend","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine, University of Oxford , Oxford OX3 9DS ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E","family":"Broderick","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals , San Diego, CA 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-5118","authenticated-orcid":false,"given":"Elma","family":"Tchilian","sequence":"additional","affiliation":[{"name":"The Pirbright Institute , Pirbright GU24 0NF ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"2025030417504388600_r1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41594-018-0025-9","article-title":"Structural insights into the design of novel anti-influenza therapies","volume":"25","author":"Wu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2025030417504388600_r2","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"MBio"},{"key":"2025030417504388600_r3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"2025030417504388600_r4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"2025030417504388600_r5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"2025030417504388600_r6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"2025030417504388600_r7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"2025030417504388600_r8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"2025030417504388600_r9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"2025030417504388600_r10","article-title":"Broadly inhibiting antineuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans","volume":"94","author":"Rijal","year":"2019","journal-title":"J. Virol."},{"key":"2025030417504388600_r11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2025030417504388600_r12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40262-017-0564-y","article-title":"Pharmacokinetics of MHAA4549A, an anti-influenza A monoclonal antibody, in healthy subjects challenged with Influenza A virus in a phase IIa randomized trial","volume":"57","author":"Deng","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"2025030417504388600_r13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"2025030417504388600_r14","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1016\/j.vaccine.2016.08.057","article-title":"Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications","volume":"34","author":"Sparrow","year":"2016","journal-title":"Vaccine"},{"key":"2025030417504388600_r15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0300985813513043","article-title":"Influenza A virus infections in swine: pathogenesis and diagnosis","volume":"51","author":"Janke","year":"2014","journal-title":"Vet. Pathol."},{"key":"2025030417504388600_r16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ilar\/ilv002","article-title":"Swine as a model for influenza A virus infection and immunity","volume":"56","author":"Rajao","year":"2015","journal-title":"ILAR J."},{"key":"2025030417504388600_r17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000053994","article-title":"Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA","volume":"43","author":"Manam","year":"2000","journal-title":"Intervirology"},{"key":"2025030417504388600_r18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"2025030417504388600_r19","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1128\/JVI.79.23.14793-14803.2005","article-title":"Characterization of adeno-associated virus genomes isolated from human tissues","volume":"79","author":"Schnepp","year":"2005","journal-title":"J. Virol."},{"key":"2025030417504388600_r20","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/JVI.76.9.4580-4590.2002","article-title":"Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors","volume":"76","author":"Zaiss","year":"2002","journal-title":"J. Virol."},{"key":"2025030417504388600_r21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"2025030417504388600_r22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"2025030417504388600_r23","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","article-title":"Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection","volume":"9","author":"Tiwari","year":"2018","journal-title":"Nat. Commun."},{"key":"2025030417504388600_r24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ymthe.2019.03.005","article-title":"In Vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against zika virus","volume":"27","author":"Esquivel","year":"2019","journal-title":"Mol. Ther."},{"key":"2025030417504388600_r25","first-page":"1982","volume-title":"Cell. Rep.","author":"Patel","year":"2018"},{"key":"2025030417504388600_r26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126086","article-title":"DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","journal-title":"JCI Insight"},{"key":"2025030417504388600_r27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","article-title":"DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections","volume":"2","author":"Elliott","year":"2017","journal-title":"NPJ Vaccines"},{"key":"2025030417504388600_r28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fimmu.2018.00865","article-title":"Therapeutic administration of broadly neutralizing FI6 antibody reveals lack of interaction between human IgG1 and pig Fc receptors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front. Immunol."},{"key":"2025030417504388600_r29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"2025030417504388600_r30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J. Clin. Invest."},{"key":"2025030417504388600_r31","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1172\/JCI81104","article-title":"Focused antibody response to influenza linked to antigenic drift","volume":"125","author":"Huang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2025030417504388600_r32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/030098589503200606","article-title":"Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus","volume":"32","author":"Halbur","year":"1995","journal-title":"Vet. Pathol."},{"key":"2025030417504388600_r33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13567-014-0085-8","article-title":"Heterogeneous pathological outcomes after experimental pH1N1 influenza infection in ferrets correlate with viral replication and host immune responses in the lung","volume":"45","author":"Vida\u00f1a","year":"2014","journal-title":"Vet. Res. (Faisalabad)"},{"key":"2025030417504388600_r34","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.4049\/jimmunol.1502632","article-title":"Aerosol delivery of a candidate universal influenza vaccine reduces viral load in pigs challenged with pandemic H1N1 virus","volume":"196","author":"Morgan","year":"2016","journal-title":"J. Immunol."},{"key":"2025030417504388600_r35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/0300985812439724","article-title":"Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A\/H1N1 influenza virus","volume":"49","author":"Gauger","year":"2012","journal-title":"Vet. Pathol."},{"key":"2025030417504388600_r36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.virol.2019.06.004","article-title":"Deep sequencing of 2009 influenza A\/H1N1 virus isolated from volunteer human challenge study participants and natural infections","volume":"534","author":"Xiao","year":"2019","journal-title":"Virology"},{"key":"2025030417504388600_r37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"2025030417504388600_r38","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025030417504388600_r39","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3389\/fmicb.2018.02596","article-title":"Seasonal genetic drift of human influenza A virus quasispecies revealed by deep sequencing","volume":"9","author":"Barbezange","year":"2018","journal-title":"Front. Microbiol."},{"key":"2025030417504388600_r40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2016.03.005","article-title":"Next generation sequencing for whole genome analysis and surveillance of influenza A viruses","volume":"79","author":"McGinnis","year":"2016","journal-title":"J. Clin. Virol."},{"key":"2025030417504388600_r41","doi-asserted-by":"crossref","DOI":"10.1128\/mSphereDirect.00462-18","article-title":"Deep sequencing of H7N9 influenza A viruses from 16 infected patients from 2013 to 2015 in shanghai reveals genetic diversity and antigenic drift","volume":"3","author":"Xiao","year":"2018","journal-title":"MSphere"},{"key":"2025030417504388600_r42","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1128\/JVI.01820-12","article-title":"Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity","volume":"86","author":"Powell","year":"2012","journal-title":"J. Virol."},{"key":"2025030417504388600_r43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/hum.2018.241","article-title":"Active immunoprophylaxis and vaccine augmentations mediated by a novel plasmid DNA formulation","volume":"30","author":"Schommer","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"2025030417504388600_r44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1084\/jem.20130212","article-title":"Immune history shapes specificity of pandemic H1N1 influenza antibody responses","volume":"210","author":"Li","year":"2013","journal-title":"J. Exp. Med."},{"key":"2025030417504388600_r45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11095-019-2574-y","article-title":"The binding of human IgG to minipig Fc\u03b3Rs - implications for preclinical assessment of therapeutic antibodies","volume":"36","author":"Egli","year":"2019","journal-title":"Pharm. Res."},{"key":"2025030417504388600_r46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2018.1540586","article-title":"Animal models used to assess influenza antivirals","volume":"13","author":"Mifsud","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"2025030417504388600_r47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/978-1-4939-8678-1_20","article-title":"Animal models in influenza research","volume":"1836","author":"Hemmink","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"2025030417504388600_r48","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal models for influenza virus pathogenesis and transmission","volume":"2","author":"Bouvier","year":"2010","journal-title":"Viruses"},{"key":"2025030417504388600_r49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/pathogens3040845","article-title":"Animal models for influenza viruses: implications for universal vaccine development","volume":"3","author":"Margine","year":"2014","journal-title":"Pathogens"},{"key":"2025030417504388600_r50","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model","volume":"7","author":"Memoli","year":"2016","journal-title":"MBio"},{"key":"2025030417504388600_r51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/ciu924","article-title":"Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study","volume":"60","author":"Memoli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"2025030417504388600_r52","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"Roestenberg","year":"2018","journal-title":"Lancet Infect. Dis."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/205\/3\/648\/61879813\/ji2000429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/205\/3\/648\/61879813\/ji2000429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:57:31Z","timestamp":1741093051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/205\/3\/648\/7930973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2000429","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.12.988808","asserted-by":"object"}]},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,8,1]]}}}